Pharmacokinetics of plasma‐derived C1‐esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study
Open Access
- 24 November 2013
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 54 (6), 1552-1561
- https://doi.org/10.1111/trf.12501
Abstract
Background Hereditary angioedema (HAE) is a rare disease caused by C1‐esterase inhibitor (C1‐INH) deficiency, characterized by periodic attacks of acute edema affecting subcutaneous (SC) tissues and mucous membranes. Human C1‐INH concentrate given intravenously (IV) is effective and safe, but venous access may be difficult. We compared SC and IV administration of human pasteurized C1‐INH concentrate with respect to pharmacokinetics, pharmacodynamics, and safety. Study Design and Methods This was a prospective, randomized, open‐label, crossover study. Twenty‐four subjects with mild or moderate HAE were randomly assigned during an attack‐free interval to receive 1000 units of human pasteurized C1‐INH concentrate IV or SC. Plasma levels of C1‐INH activity and antigen, C4 antigen, cleaved high‐molecular‐weight kininogen (clHK), and C1‐INH antibodies were measured. Results The mean relative bioavailability of functional C1‐INH after SC administration was 39.7%. Maximum C1‐INH activity after SC administration occurred within 48 hours and persisted longer than after IV administration. C4 antigen levels increased and clHK levels decreased after IV and SC administration, indicating the pharmacodynamic action of C1‐INH. The mean half‐life of functional C1‐INH was 62 hours after IV administration and 120 hours after SC administration (p = 0.0595). C1‐INH concentrate was safe and well tolerated when administered via both routes. As expected, SC administration resulted in a higher incidence of injection site reactions, all of which were mild. Conclusion With a relative bioavailability of 39.7%, SC administration of human pasteurized C1‐INH yields potentially clinically relevant and sustained plasma levels of C1‐INH and is safe and well tolerated.Keywords
Funding Information
- CSL Behring Foundation for Research and Advancement of Patient Health
This publication has 43 references indexed in Scilit:
- Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneous (SC) Cinryze® (C1 inhibitor (C1 INH) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with Hereditary Angioedema (HAE)Journal of Allergy and Clinical Immunology, 2012
- C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 studyAllergy, 2011
- 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaAllergy, Asthma & Clinical Immunology, 2010
- Diagnosis and treatment of hereditary angioedema with normal C1 inhibitorAllergy, Asthma & Clinical Immunology, 2010
- Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary AngioedemaJournal of Clinical Immunology, 2010
- Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyondJournal of Allergy and Clinical Immunology, 2004
- Asphyxiation by Laryngeal Edema in Patients With Hereditary AngioedemaMayo Clinic Proceedings, 2000
- Vascular endothelial cell activation and permeability responses to thrombinBlood Coagulation & Fibrinolysis, 1995
- The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiencyJournal of Allergy and Clinical Immunology, 1986
- Half‐life of CINH in hereditary angioneurotic oedema (HAE)*Clinical and Experimental Allergy, 1975